Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Sihuan and Japan's RaQualia to Collaborate on Analgesic Drugs

publication date: Dec 28, 2015
Sihuan Pharma entered a three-year collaboration with RaQualia Pharma of Japan to develop novel drug candidates for pain relief. The two companies will employ multiple lead-discovery technologies, including high-throughput screening technology, to identify promising candidates for a specific ion channel target. Sihuan will own greater China rights to any products developed by the collaboration, and RaQualia will share in ex-China profits. Sihuan will carry out the work through its Shandong XuanZhu Pharma subsidiary. More details....

Stock Symbol: (HK: 0460)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital